姑息性放射治疗后的间质光动力疗法治疗无法手术的恶性中央气道梗阻患者
无法手术的恶性中央气道梗阻患者姑息放疗后间质光动力治疗的 I/II 期研究
This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the patient at a higher risk for respiratory failure, post-obstructive pneumonia, and prolonged hospitalizations. Treatment for these patients may include bronchoscopic intervention (such as mechanical removal, stenting, laser cauterization, or ballooning), radiation therapy with and without chemotherapy. While palliative x-ray radiotherapy may help in shrinking the tumor, high dose curative radiotherapy that can ablate (a localized, nonsurgical destruction) the tumor also has high risk to cause significant toxicity, including bleeding, abnormal connections or passageways between organs or vessels and abnormal scar tissue that can also produce airway obstruction. Photodynamic therapy (PDT) is another possible treatment that can provide local control of the tumor. PDT consists of injecting a light sensitive drug (photosensitizer, PS) into the vein, waiting for the PS to accumulate in the tumor, and then activating it with a red laser light. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving interstitial photodynamic therapy following palliative radiotherapy may improve tumor response and survival without the serious side effects that are associated with the typical high dose curative x-ray radiotherapy alone in patients with malignant central airway obstruction.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVES:
I. To test the safety of our image-based treatment planning for image-guided interstitial photodynamic therapy (I PDT) with endobronchial ultrasound (EBUS) following standard of care palliative radiotherapy (p-XRT). (Phase I)
-To assess the efficacy of our image-based treatment planning for image-guided I-PDT following standard of care p-XRT. (Phase II)
SECONDARY OBJECTIVES:
- To assess objective tumor response. (Phase I)
- To evaluate changes in quality of life. (Phase I and II)
- To measure changes in functional lung capacity. (Phase I and II)
- To measure the relationship between the measured objective tumor response (at 12 +/- 2 weeks post I-PDT) and changes in therapeutic laser light transmission within the target tumor, as a future dosimetric marker for response. (Phase I and II)
- To assess treatment effects on the immune contexture. (Phase I and II)
- To monitor progression free survival. (Phase I and II)
OUTLINE: This is a phase I study, followed by a phase II.
PHASE I: Patients are assigned to 1 of 2 cohorts.
COHORT 1: Patients receive visudyne intravenously (IV) over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo computed tomography (CT) throughout the trial.
COHORT 2: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
PHASE II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
After completion of study treatment, patients are followed up at 30 days and 8, 12, and 24 weeks.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:ASKRPCI@RoswellPark.org
- 电话号码:1-877-275-7724
- 邮箱:askrpci@roswellpark.org
学习地点
-
-
New York
-
Buffalo、New York、美国、14263
- 招聘中
- Roswell Park Cancer Institute
-
接触:
- Nathaniel Ivanick
- 电话号码:716-845-5873
- 邮箱:Nathaniel.Ivanick@RoswellPark.org
-
首席研究员:
- Nathaniel Ivanick
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Abramson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age >= 18 years of age
- Eligibility checklist before registration requires review of case by the interventional pulmonologist/s and radiation oncologist/s to approve anatomic feasibility of an airway intervention and palliative radiotherapy
- Patients with pathologic diagnosis of inoperable solid malignancy involving extrabronchial tumor growth that causes airway obstruction and not amenable to curative radiotherapy. All patients will have tumors requiring bronchoscopic intervention with endobronchial ultrasound (EBUS) at the time of I-PDT
- Participants have at least one measurable lesion which is also the target lesion for Response Evaluation Criteria in Solid Tumors (RECIST) measurement
- Patients amenable to receive standard of care palliative radiotherapy to the target tumor, as determined by the radiation oncologist/s
- Amenable to high resolution chest computed tomography (CT) scan (with or without contrast due to contraindication) with 0.625-1.25 mm slice thickness and slice interval 0.5-1 mm
- Tumor is accessible and amenable to I-PDT, as determined by the interventional pulmonologist/s
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3
- Platelets ≥ 100,000 cells/mm^3 (International System of Units [SI] units 100 x 10^9/L)
- International normalized ratio (INR) < 1.5 and activated partial thromboplastin time (aPTT) < 1.5 x ULN. PTT or aPTT per institutional standards for participating external sites
- Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 3 months after receiving the study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Pregnant or nursing female participants
- Co-existing ophthalmic disease likely to require slit-lamp examination within the next 30 days following I-PDT treatment
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the I-PDT
- CT imaging suggestive of target tumor invasion into a major blood vessel (typically proximal to segmental vessels)
- Known hypersensitivity/allergy to porphyrin
- Patients who are not cleared by the anesthesiologist to undergo an advanced bronchoscopy procedure under general anesthesia
- Patients who have received 120 Gy total radiation dose delivered to a structure within 1 cm margin of tumor volume to be targeted by p-XRT and I-PDT
- Patients diagnosed with porphyria
- Patients with known allergy to eggs
- Patients unwilling or unable to follow protocol requirements
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase I cohort 1 (I-PDT, EBUS)
Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial. |
Undergo CT
其他名称:
Ancillary studies Undergo blood and tissue sample collection
其他名称:
Ancillary studies
其他名称:
Undergo EBUS
其他名称:
Undergo I-PDT
其他名称:
Given IV
其他名称:
|
|
实验性的:Phase I cohort 2 (I-PDT, EBUS, palliative radiation therapy)
Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial. |
Undergo CT
其他名称:
Ancillary studies Undergo blood and tissue sample collection
其他名称:
Ancillary studies
其他名称:
Undergo EBUS
其他名称:
Undergo I-PDT
其他名称:
Given IV
其他名称:
Undergo palliative radiation therapy
其他名称:
Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
其他名称:
|
|
实验性的:Phase II (I-PDT, EBUS, palliative radiation therapy)
Phase II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial. |
Undergo CT
其他名称:
Ancillary studies Undergo blood and tissue sample collection
其他名称:
Ancillary studies
其他名称:
Undergo EBUS
其他名称:
Undergo I-PDT
其他名称:
Undergo palliative radiation therapy
其他名称:
Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of >= grade 3 adverse events (Phase I)
大体时间:Within 30 days post interstitial photodynamic therapy (I-PDT)
|
Will will be associated with treatment related adverse events .grade 3 (with attribution of 'possible', 'probable' or 'definite'. Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0). |
Within 30 days post interstitial photodynamic therapy (I-PDT)
|
|
Overall tumor response (Phase II)
大体时间:At 12 weeks post I-PDT
|
Will be assessed by complete response (CR) or partial response (PR) defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) criteria. |
At 12 weeks post I-PDT
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall tumor response (Phase I)
大体时间:At 12 weeks post I-PDT
|
Will be assessed by CR or PR defined by the RECIST v 1.1 criteria. |
At 12 weeks post I-PDT
|
|
Quality of life (Phase I and II)
大体时间:At study enrollment, immediately prior to p-XRT and I-PDT, and at 4 and 12 weeks
|
Will be monitored using the Functional Assessment of Cancer Therapy-Lung. This 36 item self-reported quality of life questionnaire measures responses across six domains: physical well-being, social/family well-being, relationship with doctor, emotional well-being, functional well-being, and additional concerns. This scale was chosen because multiple studies support its validity and use in clinical trials of lung cancer. |
At study enrollment, immediately prior to p-XRT and I-PDT, and at 4 and 12 weeks
|
|
Functional lung capacity (Phase I and II)
大体时间:At study entry (baseline), 30 days and 12 weeks
|
Will be measured with the six-minute walk test. |
At study entry (baseline), 30 days and 12 weeks
|
|
Change in the therapeutic laser light transmission (Phase I and II)
大体时间:During the I-PDT
|
Will be measured with our light dosimetry system. |
During the I-PDT
|
|
Association between immune markers and tumor response (Phase I and II)
大体时间:Prior and 7-10 days after the I-PDT
|
will be measured with flow cytometry in fresh blood samples collected prior and 7-10 days after the I-PDT. |
Prior and 7-10 days after the I-PDT
|
|
Progression free survival (Phase I and II)
大体时间:Time from date of study treatment to the time of first observed disease progression (RECIST 1.1 criteria) at the treated tumor site or, death due to any cause, assessed up to 5 years
|
Will be summarized using standard Kaplan-Meier methods. |
Time from date of study treatment to the time of first observed disease progression (RECIST 1.1 criteria) at the treated tumor site or, death due to any cause, assessed up to 5 years
|
合作者和调查者
调查人员
- 首席研究员:Nathaniel Ivanick、Roswell Park Cancer Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- I-3901323
- I-3901323 (其他标识符:Roswell Park Cancer Institute)
- NCI-2024-01239 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- R01CA283547 (美国 NIH 拨款/合同)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.